M/s. Moraf Pharmaceuticals Ltd

M/s. Moraf Pharmaceuticals Ltd is a privately held pharmaceutical company headquartered in Dar es Salaam, Tanzania. Established in 2000, the company has grown to employ between 201 and 500 individuals. It operates as an importer and distributor of pharmaceutical and surgical products, aiming to ensure the accessibility of safe, effective, and affordable healthcare products across Tanzania. Their primary imports originate from countries such as India, China, and Kenya.

The company's mission focuses on reaching even the remotest areas of Tanzania, supplying hospitals, pharmacies, and medical institutions with essential healthcare products. This commitment underscores their role in enhancing the nation's healthcare infrastructure by providing a diverse range of pharmaceutical and surgical items.

Moraf Pharmaceuticals Ltd's distribution network is centralized in Dar es Salaam, with their main office located on Kipande Street in the Kariakoo area. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Dar es Salaam suggests a focus on efficient distribution within Tanzania. The choice of Dar es Salaam, a major port city, likely facilitates the importation and distribution of pharmaceutical products throughout the country.

In Tanzania's pharmaceutical supply chain, Moraf Pharmaceuticals Ltd functions primarily as a wholesaler and distributor. By importing pharmaceutical and surgical products and supplying them to hospitals, pharmacies, and medical institutions, the company plays a crucial role in ensuring the availability of essential healthcare products across the nation. Their operations are integral to the healthcare sector, supporting the delivery of medical services by providing necessary supplies.

Moraf Pharmaceuticals Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value of $450,000 USD from India across nine shipments, all sourced from a single supplier: FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED. This single-source dependency indicates a strategic choice to maintain a consistent supply chain and potentially leverage favorable terms with a trusted supplier. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier terms. The absence of alternative suppliers in the data suggests a need for diversification to mitigate potential risks.

The resilience of Moraf Pharmaceuticals Ltd's supply chain appears limited due to its reliance on a single supplier for all imports. This lack of diversification could expose the company to significant risks if the supplier faces operational challenges or if there are disruptions in the shipping routes from India. Additionally, the data does not indicate the presence of backup suppliers or a diverse range of formulations, which are essential for maintaining a robust supply chain. Ensuring regulatory compliance of the key supplier is crucial, as any lapses could directly impact Moraf Pharmaceuticals Ltd's operations.

The current sourcing pattern of Moraf Pharmaceuticals Ltd, characterized by a high concentration on a single supplier, may offer short-term benefits such as streamlined operations and potentially better pricing. However, this strategy could limit the company's competitive position in the long term due to increased vulnerability to supply chain disruptions. For Indian exporters, this presents an opportunity to introduce alternative suppliers to Moraf Pharmaceuticals Ltd, offering competitive pricing, diverse product formulations, and reliable delivery schedules to meet the company's needs.

In Tanzania, the Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of medicines and medical devices. Established under the Tanzania Medicines and Medical Devices Act, Cap. 219, TMDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Tanzanian market. (tmda.go.tz)

The regulatory framework governing pharmaceutical imports includes the Pharmaceutical and Poisons Act, which stipulates that no person shall import any pharmaceutical product unless it is registered and the importer holds the appropriate license issued by the Board. This legislation ensures that all imported pharmaceutical products meet the required standards before entering the Tanzanian market.

Importers of pharmaceutical products in Tanzania must obtain an import license from TMDA. The application process involves submitting necessary documents and paying the prescribed fees. Importers are also required to register their premises with TMDA before applying for permits. Compliance with the conditions prescribed under the Guidelines for Importation and Exportation of Pharmaceutical Products is mandatory. (tmda.go.tz)

Regarding Good Manufacturing Practice (GMP), imported pharmaceutical products must come from facilities that adhere to recognized GMP standards. TMDA requires that pharmaceutical products imported into Tanzania be from manufacturers with GMP certification to ensure product quality and safety. (tmda.go.tz)

Imported pharmaceutical products must undergo batch testing to verify their quality and safety. The remaining shelf-life of the product is also a critical factor; products with a shelf-life of more than 24 months must have at least 60% of their shelf-life remaining, while those with a shelf-life of 24 months or less must have at least 80% remaining. (tmda.go.tz)

Labeling requirements include providing information in the English language, and the labels must contain specific details such as the product name, strength, dosage form, batch number, manufacturing date, expiry date, storage conditions, and the name and address of the manufacturer. Serialization mandates may also apply to ensure traceability and prevent counterfeit products. (tmda.go.tz)

Between 2024 and 2026, Tanzania has implemented several policy changes affecting pharmaceutical imports. These include stricter enforcement of GMP standards for imported products, updated labeling requirements to enhance consumer safety, and revised import licensing procedures to streamline the approval process. Additionally, there has been an increased emphasis on ensuring the remaining shelf-life of imported pharmaceutical products meets the required standards. (tmda.go.tz)

Moraf Pharmaceuticals Ltd's focus on importing antifungal and respiratory medications aligns with the prevalent health concerns in Tanzania. The significant import value of fluconazole and salbutamol indicates a strategic approach to addressing common medical conditions such as fungal infections and respiratory disorders. This product strategy is driven by market demand and the company's commitment to providing essential healthcare solutions to the Tanzanian population.

Moraf Pharmaceuticals Ltd's sourcing strategy is heavily reliant on importing finished pharmaceutical formulations from India, particularly from FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED. This approach suggests a preference for ready-to-use products that meet the company's quality standards. The focus on finished formulations indicates a streamlined procurement process, allowing the company to efficiently supply the Tanzanian market with essential medications.

Based on its product mix, Moraf Pharmaceuticals Ltd serves a broad segment of the Tanzanian market, including retail pharmacies, hospitals, and government tenders. By supplying essential medications such as antifungals and respiratory drugs, the company plays a pivotal role in the healthcare supply chain, ensuring that various healthcare providers have access to necessary pharmaceutical products.

There is a realistic opportunity for new Indian suppliers to engage with Moraf Pharmaceuticals Ltd. The company's current sourcing pattern, characterized by a high concentration on a single supplier, presents an opportunity for diversification. Indian exporters can offer competitive pricing, diverse product formulations, and reliable delivery schedules to meet the company's needs. Identifying gaps in the current sourcing strategy, such as the need for additional suppliers or alternative products, can further enhance the partnership potential.

Indian exporters seeking to supply Moraf Pharmaceuticals Ltd and the Tanzanian market must ensure that their products are registered with TMDA. Compliance with TMDA's import licensing requirements, including the registration of premises and adherence to GMP standards, is mandatory. Additionally, products must meet labeling requirements, including information in the English language and specific product details. Ensuring that products have an adequate remaining shelf-life upon importation is also crucial. (tmda.go.tz)

To establish a relationship with Moraf Pharmaceuticals Ltd, Indian exporters should initiate contact by providing detailed product information, including certifications and compliance with Tanzanian regulations. Participating in tenders and responding to requests for proposals can also be effective strategies. Understanding the regulatory filing process and ensuring timely submission of necessary documents will facilitate smoother interactions. Setting realistic timelines for product registration and importation, in line with TMDA's processing times, will help manage expectations and build a strong partnership.